<p>Tarsus Pharmaceuticals, Inc.（納斯達克代碼：TARS - 獲取免費報告）在週一的交易中，其股價達到了新的 52 周高點。該股最高交易價為 57.14 美元，最後交易價為 56.17 美元，成交量為 228758 股。該股此前收盤價為 55.00 美元。</p>
<p>獲取 <strong>Tarsus Pharmaceuticals</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<p>多家券商對 TARS 發佈了報告。Oppenheimer 將 Tarsus Pharmaceuticals 的目標價從 63.00 美元上調至 65.00 美元，並在 11 月 14 日的報告中給予該股 “跑贏大盤” 的評級。高盛集團將 Tarsus Pharmaceuticals 的目標價從 36.00 美元上調至 41.00 美元，並在 11 月 15 日的報告中給予該公司 “中性” 的評級。一位股票研究分析師對該股給予了持有評級，四位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “買入”，平均目標價為 54.20 美元。</p>
<p><strong>閲讀我們關於 TARS 的最新報告</strong></p>
<h2>Tarsus Pharmaceuticals 價格表現</h2>
<p>該公司的市值為 21.4 億美元，市盈率為-14.67，貝塔值為 1.04。該公司的流動比率為 5.42，速動比率為 5.38，債務權益比為 0.30。該公司的 50 日移動平均價格為 48.24 美元，200 日移動平均價格為 35.82 美元。</p>
<h2>機構投資者對 Tarsus Pharmaceuticals 的看法</h2>
<p>多家機構投資者和對沖基金最近增加或減少了在 TARS 的持股。Quest Partners LLC 在第二季度以 61,000 美元的估值收購了 Tarsus Pharmaceuticals 的新股份。加拿大養老金計劃投資委員會在第二季度以 114,000 美元的估值收購了 Tarsus Pharmaceuticals 的新股份。FMR LLC 在第三季度將其在 Tarsus Pharmaceuticals 的持股增加了 236.6%。FMR LLC 目前擁有 5,032 股該公司的股票，價值 166,000 美元，此前在此期間又購買了 3,537 股。蘇黎世州立銀行在第二季度將其在 Tarsus Pharmaceuticals 的持股增加了 33.4%。蘇黎世州立銀行目前擁有 6,109 股該公司的股票，價值 166,000 美元，此前在上個季度又購買了 1,530 股。最後，SG Americas Securities LLC 在第三季度將其在 Tarsus Pharmaceuticals 的持股增加了 87.5%。SG Americas Securities LLC 目前擁有 7,242 股該公司的股票，價值 238,000 美元，此前在此期間又購買了 3,379 股。對沖基金和其他機構投資者持有該公司 90.01% 的股票。</p>
<h2>Tarsus Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Tarsus Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於在美國開發和商業化新型眼科治療候選藥物。該公司的主要產品候選藥物是 XDEMVY，一種用於治療由蟎蟲感染引起的瞼板腺炎的新型治療藥物，以及用於治療瞼板腺疾病。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Tarsus Pharmaceuticals</li>
<li>特殊目的收購公司（SPAC）你需要知道的事項</li>
<li>2025 年必須持有的三隻股票，具有兩位數的上漲潛力</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>美光：為什麼現在是勇敢的時候</li>
<li>如何投資 FAANG 股票</li>
<li>三隻華爾街內部人士無法停止購買的股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<p>→ 釋放病毒特朗普視頻（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0NQ"/></p>
<h2>你現在應該投資 1,000 美元在 Tarsus Pharmaceuticals 嗎？</h2>
<p>在你考慮 Tarsus Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Tarsus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Tarsus Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

TARS

<p>Tarsus Pharmaceuticals（納斯達克代碼：TARS）在交易中達到了新的 52 周高點 57.14 美元，收盤價為 56.17 美元。分析師們提高了價格目標，Oppenheimer 將其目標上調至 65.00 美元，高盛則上調至 41.00 美元。該股票的共識評級為 “買入”，平均價格目標為 54.20 美元。機構投資者持有該股票的 90.01%，公司專注於開發眼科治療，特別是其主要產品 XDEMVY 用於治療瞼炎</p>

<p>Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $57.14 and last traded at $56.17, with a volume of 228758 shares trading hands. The stock had previously closed at $55.00.</p>
<div class="lb-trans"><p>Tarsus Pharmaceuticals, Inc.（納斯達克代碼：TARS - 獲取免費報告）在週一的交易中，其股價達到了新的 52 周高點。該股最高交易價為 57.14 美元，最後交易價為 56.17 美元，成交量為 228758 股。該股此前收盤價為 55.00 美元。</p>
</div><p>Get <strong>Tarsus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tarsus Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages have issued reports on TARS. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, November 14th. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and an average price target of $54.20.</p>
<div class="lb-trans"><p>多家券商對 TARS 發佈了報告。Oppenheimer 將 Tarsus Pharmaceuticals 的目標價從 63.00 美元上調至 65.00 美元，並在 11 月 14 日的報告中給予該股 “跑贏大盤” 的評級。高盛集團將 Tarsus Pharmaceuticals 的目標價從 36.00 美元上調至 41.00 美元，並在 11 月 15 日的報告中給予該公司 “中性” 的評級。一位股票研究分析師對該股給予了持有評級，四位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “買入”，平均目標價為 54.20 美元。</p>
</div><p><strong>Read Our Latest Report on TARS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 TARS 的最新報告</strong></p>
</div><h2>Tarsus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 價格表現</h2>
</div><p>The firm has a market capitalization of $2.14 billion, a PE ratio of -14.67 and a beta of 1.04. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a fifty day moving average price of $48.24 and a two-hundred day moving average price of $35.82.</p>
<div class="lb-trans"><p>該公司的市值為 21.4 億美元，市盈率為-14.67，貝塔值為 1.04。該公司的流動比率為 5.42，速動比率為 5.38，債務權益比為 0.30。該公司的 50 日移動平均價格為 48.24 美元，200 日移動平均價格為 35.82 美元。</p>
</div><h2>Institutional Investors Weigh In On Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Tarsus Pharmaceuticals 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in TARS. Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at $114,000. FMR LLC increased its stake in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after purchasing an additional 3,537 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after buying an additional 1,530 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock worth $238,000 after buying an additional 3,379 shares during the period. Hedge funds and other institutional investors own 90.01% of the company's stock.</p>
<div class="lb-trans"><p>多家機構投資者和對沖基金最近增加或減少了在 TARS 的持股。Quest Partners LLC 在第二季度以 61,000 美元的估值收購了 Tarsus Pharmaceuticals 的新股份。加拿大養老金計劃投資委員會在第二季度以 114,000 美元的估值收購了 Tarsus Pharmaceuticals 的新股份。FMR LLC 在第三季度將其在 Tarsus Pharmaceuticals 的持股增加了 236.6%。FMR LLC 目前擁有 5,032 股該公司的股票，價值 166,000 美元，此前在此期間又購買了 3,537 股。蘇黎世州立銀行在第二季度將其在 Tarsus Pharmaceuticals 的持股增加了 33.4%。蘇黎世州立銀行目前擁有 6,109 股該公司的股票，價值 166,000 美元，此前在上個季度又購買了 1,530 股。最後，SG Americas Securities LLC 在第三季度將其在 Tarsus Pharmaceuticals 的持股增加了 87.5%。SG Americas Securities LLC 目前擁有 7,242 股該公司的股票，價值 238,000 美元，此前在此期間又購買了 3,379 股。對沖基金和其他機構投資者持有該公司 90.01% 的股票。</p>
</div><h2>Tarsus Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.</p>
<div class="lb-trans"><p>Tarsus Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於在美國開發和商業化新型眼科治療候選藥物。該公司的主要產品候選藥物是 XDEMVY，一種用於治療由蟎蟲感染引起的瞼板腺炎的新型治療藥物，以及用於治療瞼板腺疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Tarsus Pharmaceuticals</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>3 Must-Hold Stocks with Double-Digit Upside for 2025</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Micron: Why Now Is the Time to Be Brave</li>
<li>How to Invest in the FAANG Stocks</li>
<li>3 Stocks That Wall Street Insiders Can’t Stop Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Tarsus Pharmaceuticals</li>
<li>特殊目的收購公司（SPAC）你需要知道的事項</li>
<li>2025 年必須持有的三隻股票，具有兩位數的上漲潛力</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>美光：為什麼現在是勇敢的時候</li>
<li>如何投資 FAANG 股票</li>
<li>三隻華爾街內部人士無法停止購買的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><p>→ Viral Trump video released (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 釋放病毒特朗普視頻（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0NQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=11145&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Tarsus Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tarsus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Tarsus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Tarsus Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Tarsus Pharmaceuticals 並不在名單上。</p>
</div><p>While Tarsus Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tarsus Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High  - Here's What Happened

Market Beat

Tarsus Pharmaceuticals（NASDAQ:TARS）創下新的 1 年高點 - 事情是這樣的